Constellation Pharmaceuticals

Constellation Pharmaceuticals Announces $100 Million Financing

Steve Iadarola — Mon, 09 Apr 2018 10:02:18 +0000

Proceeds Will Help to Advance the Company’s Cancer Epigenetics Platform and Accelerate Development of Ongoing Therapeutic Programs
CAMBRIDGE, Massachusetts, April 9, 2018 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research and development in cancer epigenetics, today announced a $100 million financing.…

The post Constellation Pharmaceuticals Announces $100 Million Financing appeared first on Constellation Pharmaceuticals.

Constellation Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference

Steve Iadarola — Fri, 16 Mar 2018 13:47:27 +0000

CAMBRIDGE, Massachusetts, March 16, 2018 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that President and Chief Executive Officer Jigar Raythatha will present a company overview at the Oppenheimer & Co.…

The post Constellation Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference appeared first on Constellation Pharmaceuticals.

Constellation Pharmaceuticals to Present at the 38th Annual Cowen and Company Health Care Conference

Steve Iadarola — Tue, 06 Mar 2018 12:39:30 +0000

CAMBRIDGE, Massachusetts, March 6, 2018 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that President and Chief Executive Officer Jigar Raythatha will present a corporate overview at the 38th Annual Cowen and Company Health Care Conference on March 12 at 11:30 a.m.…

The post Constellation Pharmaceuticals to Present at the 38th Annual Cowen and Company Health Care Conference appeared first on Constellation Pharmaceuticals.

Constellation Pharmaceuticals Announces Upcoming Presentations of Lead EZH2 and BET Clinical Programs

Steve Iadarola — Fri, 09 Feb 2018 14:18:03 +0000

CAMBRIDGE, Massachusetts, February 9, 2018 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research and development in cancer epigenetics, today announced scientific and clinical presentations on its most advanced EZH2 and BET clinical development candidates at three upcoming conferences.…

The post Constellation Pharmaceuticals Announces Upcoming Presentations of Lead EZH2 and BET Clinical Programs appeared first on Constellation Pharmaceuticals.

Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205

Chase Gobble — Mon, 15 Jan 2018 20:00:50 +0000

Demonstrates the company’s ability to utilize its platform to identify mechanisms of epigenetics-mediated drug resistance to cancer immunotherapies
Trial to evaluate the potential for the company’s most advanced small-molecule EZH2 inhibitor to be used in combination with Yervoy® and other immunotherapies
CAMBRIDGE, Massachusetts, January 16, 2018 – Constellation Pharmaceuticals, Inc.,…

The post Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 appeared first on Constellation Pharmaceuticals.

Constellation Pharmaceuticals to Present at 36th Annual JP Morgan Healthcare Conference

Chase Gobble — Wed, 03 Jan 2018 21:32:21 +0000

CAMBRIDGE, Massachusetts, January 3, 2018 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that President and Chief Executive Officer Jigar Raythatha will present a company overview at the 36th Annual JP Morgan Healthcare Conference on January 11 at 11:00 a.m.…

The post Constellation Pharmaceuticals to Present at 36th Annual JP Morgan Healthcare Conference appeared first on Constellation Pharmaceuticals.

Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer

Chase Gobble — Tue, 12 Dec 2017 12:30:09 +0000

First solid tumor study from company’s EZH2 portfolio
CAMBRIDGE, Massachusetts, December 12, 2017 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that the first patient has been dosed in its Phase 1b/2 PROSTAR study of CPI-1205, a small-molecule inhibitor of EZH2, combined with enzalutamide or abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).…

The post Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer appeared first on Constellation Pharmaceuticals.

Constellation Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

Chase Gobble — Tue, 21 Nov 2017 12:33:18 +0000

CAMBRIDGE, Massachusetts, November 21, 2017 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that President and Chief Executive Officer Jigar Raythatha will present a company overview at the 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017 at 8:50 a.m.…

The post Constellation Pharmaceuticals to Present at Piper Jaffray Healthcare Conference appeared first on Constellation Pharmaceuticals.

Constellation Pharmaceuticals Completes Management Team with Key Leadership Appointments

Chase Gobble — Tue, 24 Oct 2017 11:31:48 +0000

CAMBRIDGE, Massachusetts, October 24, 2017 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced it has appointed Emma Reeve as chief financial officer and Brad Prosek as senior vice president, corporate development.…

The post Constellation Pharmaceuticals Completes Management Team with Key Leadership Appointments appeared first on Constellation Pharmaceuticals.

Constellation Pharmaceuticals Appoints Adrian Senderowicz, M.D., as Senior Vice President and Chief Medical Officer

Chase Gobble — Tue, 18 Jul 2017 11:31:01 +0000

CAMBRIDGE, Mass. – July 18, 2017 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focusing on the development of novel tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced the appointment of Adrian Senderowicz, M.D., as senior vice president and chief medical officer.…

The post Constellation Pharmaceuticals Appoints Adrian Senderowicz, M.D., as Senior Vice President and Chief Medical Officer appeared first on Constellation Pharmaceuticals.